| |
| |
|
| Insider
Information: |
Hedley Mary Lynne |
| Relationship: |
Director |
| City: |
Lexington |
| State: |
MA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
7 |
|
| Direct
Shares |
34,620 |
|
|
Indirect Shares
|
98 |
|
|
| Direct
Value |
$2,111,492 |
|
|
|
Indirect Value
|
$78,685 |
|
|
| Total
Shares |
34,718 |
|
|
| Total
Value |
$2,190,177 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
0
|
0
|
|
Stock
price went up :
|
0
|
0
|
| Stock
price went down : |
0
|
0
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
0.0%
|
0.0%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
MGI Pharma Inc |
MOGN |
Exec VP & Chief Scient... |
2008-01-28 |
0 |
2008-01-23 |
0 |
Premium* |
|
|
New Abraxis Inc |
ABII |
Executive VP of Ops & ... |
2009-07-13 |
25,000 |
2009-07-13 |
0 |
Premium* |
|
|
Tesaro, Inc. |
TSRO |
President & COO, Direc... |
2019-01-22 |
0 |
2019-01-22 |
0 |
Premium* |
|
|
Receptos, Inc. |
RCPT |
Director |
2015-08-27 |
0 |
2015-05-28 |
0 |
Premium* |
|
|
Bluebird Bio, Inc. |
BLUE |
Director |
2018-06-20 |
3,700 |
2017-09-18 |
0 |
Premium* |
|
|
Veeva Systems Inc |
VEEV |
Director |
2024-03-01 |
4,430 |
2019-11-16 |
0 |
Premium* |
|
|
Eli Lilly & Co |
LLY |
Director |
2024-05-20 |
1,490 |
2024-05-20 |
98 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
25 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 1 of 1
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TSRO |
Tesaro, Inc. |
President & COO |
• • – |
2019-01-22 |
4 |
D |
$75.00 |
$42,267,675 |
I/I |
(563,569) |
0 |
0 |
- |
|
| TSRO |
Tesaro, Inc. |
President & COO |
• • – |
2019-01-22 |
4 |
D |
$75.00 |
$2,011,200 |
D/D |
(26,816) |
0 |
0 |
- |
|
| MOGN |
MGI Pharma Inc |
Exec VP & Chief Scientific Off |
• – – |
2008-01-28 |
4 |
D |
$41.00 |
$1,489,653 |
D/D |
(36,333) |
0 |
0 |
- |
|
| TSRO |
Tesaro, Inc. |
President & COO |
• • – |
2018-12-20 |
4 |
D |
$73.10 |
$845,913 |
D/D |
(11,572) |
26,816 |
0 |
- |
|
| MOGN |
MGI Pharma Inc |
Exec VP & Chief Scientific Off |
• – – |
2008-01-23 |
4 |
D |
$41.00 |
$614,549 |
D/D |
(14,989) |
18,250 |
0 |
- |
|
| TSRO |
Tesaro, Inc. |
President & COO |
• • – |
2018-03-01 |
4 |
AS |
$54.86 |
$211,485 |
D/D |
(3,855) |
14,998 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2023-11-20 |
4 |
A |
$597.60 |
$210,355 |
D/D |
352 |
1,403 |
0 |
- |
|
| TSRO |
Tesaro, Inc. |
President & COO |
• • – |
2018-12-20 |
4 |
OE |
$6.62 |
$154,725 |
D/D |
23,390 |
38,388 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2022-11-21 |
4 |
A |
$361.17 |
$129,660 |
D/D |
359 |
536 |
0 |
- |
|
| MOGN |
MGI Pharma Inc |
Exec VP & Chief Scientific Off |
• – – |
2008-01-23 |
4 |
D |
$41.00 |
$75,235 |
I/I |
(1,835) |
0 |
0 |
- |
|
| MOGN |
MGI Pharma Inc |
Exec VP & Chief Scientific Off |
• – – |
2007-08-31 |
4 |
D |
$23.57 |
$37,406 |
D/D |
(1,587) |
33,239 |
0 |
- |
|
| MOGN |
MGI Pharma Inc |
Exec VP & Chief Scientific Off |
• – – |
2006-09-03 |
4 |
D |
$15.06 |
$35,858 |
D/D |
(2,381) |
23,842 |
0 |
- |
|
| VEEV |
Veeva Systems Inc |
Director |
– • – |
2021-07-15 |
4 |
AS |
$314.81 |
$29,592 |
D/D |
(94) |
1,742 |
0 |
% |
|
| VEEV |
Veeva Systems Inc |
Director |
– • – |
2023-07-13 |
4 |
AS |
$208.31 |
$28,747 |
D/D |
(138) |
3,606 |
0 |
% |
|
| VEEV |
Veeva Systems Inc |
Director |
– • – |
2021-01-11 |
4 |
AS |
$288.54 |
$27,411 |
D/D |
(95) |
1,486 |
0 |
% |
|
| VEEV |
Veeva Systems Inc |
Director |
– • – |
2021-04-14 |
4 |
AS |
$270.66 |
$25,713 |
D/D |
(95) |
1,614 |
0 |
% |
|
| VEEV |
Veeva Systems Inc |
Director |
– • – |
2023-07-12 |
4 |
AS |
$207.20 |
$19,062 |
D/D |
(92) |
3,744 |
0 |
% |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2024-05-20 |
4 |
A |
$783.18 |
$10,181 |
D/D |
13 |
1,490 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2024-01-16 |
4 |
A |
$634.57 |
$10,153 |
D/D |
16 |
1,437 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2022-09-19 |
4 |
A |
$305.09 |
$10,068 |
D/D |
33 |
147 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2023-04-17 |
4 |
A |
$372.35 |
$10,053 |
D/D |
27 |
930 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2022-08-15 |
4 |
A |
$313.94 |
$10,046 |
D/D |
32 |
114 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2022-12-19 |
4 |
A |
$357.78 |
$10,018 |
D/D |
28 |
565 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2023-01-17 |
4 |
A |
$357.74 |
$10,017 |
D/D |
28 |
593 |
0 |
- |
|
| LLY |
Eli Lilly & Co |
Director |
– • – |
2023-03-20 |
4 |
A |
$333.60 |
$10,008 |
D/D |
30 |
655 |
0 |
- |
|
25 Records found
|
1
|
Page 1 of 1 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
